GlobeNewswire

Mandalay Resources Corporation Announces Production and Sales Results for the Second Quarter of 2018

Dela

TORONTO, July 10, 2018 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX:MND) (OTCQB:MNDJF) announced today its production and sales results for the second quarter of 2018.

Mandalay produced a consolidated 22,348 saleable ounces of gold equivalent and sold 22,052 ounces of gold equivalent in the second quarter of 2018.

Dominic Duffy, President and Chief Executive Officer of Mandalay, commented, "The second quarter of 2018 was a transitional production and sales quarter for Mandalay as the Company began to transition production into the Brunswick Lode at Costerfield. Over the next two quarters we expect to see production lift at both operations due to the initiation of mining operations at Brunswick, and mining anticipated higher grades at Björkdal.  Consequently, the Company remains confident that it will reach its 2018 production guidance of 101,000 to 113,000 gold equivalent ounces."

Mr. Duffy continued, "Björkdal produced 14,017 ounces of gold in the second quarter of 2018. The Company is in the process of adding automation controls to the processing plant and we are beginning to see additional recovery improvements of approximately 1% as the circuit stabilizes. This is also expected to result in the removal of more gold in the gravity circuit, with the overall impact of improving our payables."

Mr. Duffy concluded, "Costerfield produced 8,331 gold equivalent ounces in the second quarter of 2018. Second quarter production was lower than in the previous year quarter due to a combination of expected lower mining grades and available ore in the current producing areas. The Company intercepted the Brunswick Lode during the second quarter and is currently dewatering this Lode. We expect a significant increase in production once dewatering is completed and mining initiated during the third quarter. Simultaneously, we are aggressively continuing our infill and extensional drilling program on the Youle lode."

Saleable production for the three months ended June 30, 2018:

  • The Company produced a total of 19,154 ounces gold and 503 tonnes antimony, representing a total of 22,348 ounces of gold equivalent production in the second quarter of 2018, versus 28,219 ounces gold, 765 tonnes of antimony and 359,457 ounces silver in the second quarter of 2017, representing a total of 38,491 ounces of gold equivalent. 
  • Production at Björkdal (Sweden) was 14,017 ounces gold in the second quarter of 2018, as compared to 16,112 ounces gold in the second quarter of 2017.
  • Production at Costerfield (Australia) was 5,137 ounces gold and 503 tonnes antimony in the second quarter of 2018, versus 8,933 ounces gold and 765 tonnes antimony in the second quarter of 2017. 
  • Production at Cerro Bayo (Chile) remains suspended; therefore, there was no production in the second quarter of 2018.

Table 1 - Second quarter and six month saleable production for 2018 and 2017

Metal Source Three months ended 
30 June 2018
Three months ended 
30 June 2017
Six months ended
30 June 2018
Six months ended
30 June 2017
Gold (oz) Björkdal 14,017 16,112 26,733 26,760
  Costerfield 5,137 8,933 11,724 16,920
  Cerro Bayo - 3,174 - 5,909
  Total 19,154 28,219 38,457 49,589
Antimony (t) Costerfield 503 765 1,108 1,506
Silver (oz) Cerro Bayo - 359,457 - 794,533
Average quarterly prices:          
Gold US$/oz   1,307 1,256    
Antimony US$/t   8,295 8,816    
Silver US$/oz   16.55 17.15    
Au Eq. (oz)1 Björkdal 14,017 16,112 26,733 26,760
  Costerfield 8,331 14,300 18,787 27,191
  Cerro Bayo - 8,079 - 17,021
  Total 22,348 38,491 45,520 70,972

1  Quarterly gold equivalent ounces ("Au Eq. oz") produced is calculated by multiplying the saleable quantities of gold ("Au"), silver ("Ag"), and antimony ("Sb") in the period by the respective average market prices of the commodities in the period, adding the three amounts to get a "total contained value based on market price", and then dividing that total contained value by the average market price of Au in the period.  Average Au price in the period is calculated as the average of the daily LME PM fixes in the period, with price on weekend days and holidays taken of the last business day; average Sb price in the period is calculated as the average of the daily average of the high and low Rotterdam warehouse prices for all days in the period, with price on weekend days and holidays taken from the last business day; average Ag price in the period is calculated as the average of the daily London Broker's silver spot price for all days in the period, with price on weekend days and holidays taken from the last business day. The source for all prices is www.metalbulletin.com.

Saleable production for the six months ended June 30, 2018:

  • The Company produced a total of 38,457 ounces gold and 1,108 tonnes antimony, representing a total of 45,520 ounces of gold equivalent production, versus 49,589 ounces gold, 1,506 tonnes of antimony and 794,533 ounces silver in the corresponding six months of 2017, representing a total of 70,972 ounces of gold equivalent.
  • Production at Björkdal was 26,733 ounces gold.
  • Production at Costerfield was 11,724 ounces gold and 1,108 tonnes antimony. 
  • Production at Cerro Bayo remains suspended; therefore, there was no production in 2018.

Sales for the three months ended June 30, 2018:

  • The Company sold 18,497 ounces gold and 560 tonnes antimony, representing a total of 22,052 ounces of gold equivalent in the second quarter of 2018, versus 24,898 ounces gold, 806 tonnes antimony, and 377,916 ounces silver in the second quarter of 2017, representing a total of 35,709 ounces of gold equivalent.
  • Björkdal sold 12,428 ounces gold in the second quarter of 2018, versus 12,752 ounces gold in the second quarter of 2017.
  • Costerfield sold 6,069 ounces gold and 560 tonnes antimony in the second quarter of 2018, versus 8,912 ounces gold and 806 tonnes antimony in the second quarter of 2017.
  • Cerro Bayo had no sales in the second quarter of 2018, as production remains suspended.

Sales for the six months ended June 30, 2018:

  • The Company sold 43,305 ounces gold and 1,239 tonnes antimony, representing a total of 51,203 ounces of gold equivalent, versus 48,564 ounces gold, 1,514 tonnes antimony, and 829,693 ounces silver in the second quarter of 2017, representing a total of 70,510 ounces of gold equivalent.
  • Björkdal sold 30,105 ounces gold.
  • Costerfield sold 13,200 ounces gold and 1,239 tonnes antimony.
  • Cerro Bayo had no sales during 2018, as production remains suspended.

Table 2 - Second quarter and six month sales for 2018 and 2017

Metal Source Three months ended 
30 June 2018
Three months ended 
30 June 2017
Six months ended
30 June 2018
Six months ended
30 June 2017
Gold (oz) Björkdal 12,428 12,752 30,105 25,873
  Costerfield 6,069 8,912 13,200 16,459
  Cerro Bayo - 3,232 - 6,232
  Total 18,497 24,896 43,305 48,564
Antimony (t) Costerfield 560 806 1,239 1,514
Silver (oz) Cerro Bayo - 377,916 - 829,693
Average quarterly prices:          
Gold US$/oz   1,307 1,256    
Antimony US$/t   8,295 8,816    
Silver US$/oz   16.55 17.15    
Au Eq. (oz)1 Björkdal 12,428 12,752 30,105 25,873
  Costerfield 9,624 14,568 21,098 26,803
  Cerro Bayo - 8,389 - 17,834
  Total 22,052 35,709 51,203 70,150

1 Quarterly Au Eq. oz sold is calculated by multiplying the saleable quantities of Au, Ag, and Sb in the period by the respective average market prices of the commodities in the period, adding the three amounts to get a "total contained value based on market price", and then dividing that total contained value by the average market price of Au for the period. The source for all prices is www.metalbulletin.com with price on weekend days and holidays taken of the last business day.

For Further Information:

Dominic Duffy
President and Chief Executive Officer

Greg DiTomaso
Director of Investor Relations

Contact: 
647.260.1566

About Mandalay Resources Corporation:

Mandalay Resources is a Canadian-based natural resource company with producing assets in Australia, Sweden and producing and exploration projects in Chile. The Company is focused on executing a roll-up strategy, creating critical mass by aggregating advanced or in-production gold, copper, silver and antimony projects in Australia, the Americas and Europe to generate near-term cash flow and shareholder value.

Forward-Looking Statements:

This news release contains "forward-looking statements" within the meaning of applicable securities laws, including statements regarding the Company's production of gold, silver and antimony for the 2018 fiscal year. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, changes in commodity prices and general market and economic conditions. The factors identified above are not intended to represent a complete list of the factors that could affect Mandalay. A description of additional risks that could result in actual results and developments differing from those contemplated by forward-looking statements in this news release can be found under the heading "Risk Factors" in Mandalay's annual information form dated March 29, 2018, a copy of which is available under Mandalay's profile at www.sedar.com. In addition, there can be no assurance that any inferred resources that are discovered as a result of additional drilling will ever be upgraded to proven or probable reserves. Although Mandalay has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Mandalay Resources Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum